ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BIOS BioPlus Acquisition Corporation

10.795
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioPlus Acquisition Corporation NASDAQ:BIOS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.795 10.79 11.28 0 01:00:00

BioScrip to Present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference

20/11/2018 2:00pm

GlobeNewswire Inc.


BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more BioPlus Acquisition Charts.

BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen M. Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference on Wednesday, December 5, 2018 at 10:10 a.m. ET at the Boca Raton Resort & Club in Boca Raton, Florida.

A live webcast of the presentation and copies of materials presented can be accessed via the Company’s Investor Relations website at https://investors.bioscrip.com/ or through the following link: https://www.veracast.com/webcasts/baml/levfin2018/id64205622087.cfm.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Contacts:

Stephen Deitsch Kalle Ahl, CFA
Chief Financial Officer & Treasurer   The Equity Group
T:  (720) 697-5200 T:  (212) 836-9614
stephen.deitsch@bioscrip.com kahl@equityny.com

                                                                                                                                                                                                                                       

 

1 Year BioPlus Acquisition Chart

1 Year BioPlus Acquisition Chart

1 Month BioPlus Acquisition Chart

1 Month BioPlus Acquisition Chart

Your Recent History

Delayed Upgrade Clock